OTCMKTS:BIOVF - Swedish Orphan Biovitrum AB (publ) Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$18.76
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Swedish Orphan Biovitrum AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIOVF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIOVF

Average Price Target: $0.00
▼ -100.00% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for Swedish Orphan Biovitrum AB (publ) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $18.76.

Hold

The current consensus among 6 polled investment analysts is to hold stock in Swedish Orphan Biovitrum AB (publ).

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/28/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings
6/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/5/2021SEB Equity ResearchDowngradeBuy ➝ Hold
5/5/2021SEB EquitiesDowngradeBuy ➝ Hold
5/5/2021DNB MarketsDowngradeBuy ➝ Hold
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageHold
3/2/2021BarclaysReiterated RatingOverweight ➝ Equal Weight
2/24/2021BarclaysDowngradeOverweight ➝ Equal Weight
2/19/2021DanskeDowngradeBuy ➝ Hold
7/22/2020BarclaysUpgradeEqual Weight ➝ Overweight
6/19/2020BarclaysUpgradeUnderweight ➝ Equal Weight
7/18/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
(Data available from 6/20/2016 forward)
Swedish Orphan Biovitrum AB (publ) logo
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact. In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus. The company has a strategic collaboration with Apellis Pharmaceuticals Inc. to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Read More

Today's Range

Now: $18.76
Low: $18.76
High: $18.76

50 Day Range

MA: $17.18
Low: $15.24
High: $19.85

52 Week Range

Now: $18.76
Low: $15.13
High: $30.00

Volume

N/A

Average Volume

746 shs

Market Capitalization

$5.63 billion

P/E Ratio

17.37

Dividend Yield

N/A

Beta

0.71

Frequently Asked Questions

What sell-side analysts currently cover shares of Swedish Orphan Biovitrum AB (publ)?

The following Wall Street research analysts have issued stock ratings on Swedish Orphan Biovitrum AB (publ) in the last twelve months: Barclays PLC, Danske, Deutsche Bank Aktiengesellschaft, DNB Markets, SEB Equities, SEB Equity Research, and Zacks Investment Research.
View the latest analyst ratings for BIOVF.

What is the current price target for Swedish Orphan Biovitrum AB (publ)?

0 Wall Street analysts have set twelve-month price targets for Swedish Orphan Biovitrum AB (publ) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Swedish Orphan Biovitrum AB (publ) in the next year.
View the latest price targets for BIOVF.

What is the current consensus analyst rating for Swedish Orphan Biovitrum AB (publ)?

Swedish Orphan Biovitrum AB (publ) currently has 6 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BIOVF, but not buy more shares or sell existing shares.
View the latest ratings for BIOVF.

What other companies compete with Swedish Orphan Biovitrum AB (publ)?

How do I contact Swedish Orphan Biovitrum AB (publ)'s investor relations team?

Swedish Orphan Biovitrum AB (publ)'s physical mailing address is Tomtebodavagen 23 A Solna, Stockholm V7, SE-112 76. The company's listed phone number is 46-8697-2000 and its investor relations email address is [email protected] The official website for Swedish Orphan Biovitrum AB (publ) is www.sobi.com.